Inloggen

Login
 
Wachtwoord vergeten?

Aandeel Novacyt PSE:ALNOV, FR0010397232

  • 3,600 7 aug 2020 17:36
  • +0,040 (+1,12%) Dagrange 3,500 - 3,680
  • 1.317.064 Gem. (3M) 2,2M

Novacyt de volgende biotech raket!

Volgen
 
Klik hier om dit forumtopic te volgen en automatisch op de hoogte gehouden te worden bij nieuwe berichten.
24.611 Posts
Pagina: 1 2 3 4 5 6 ... 1231 »» | Laatste | Omlaag ↓
  1. BiotechParels 16 september 2016 14:12
    Gister was een bizarre dag want TxCell en BioPhytis gingen met meer dan 50% omhoog….op geen nieuws! Een combinatie van een lange dalende trend waarbij er opeens geen verkopers meer waren maar wel kopers! En bij Novacyt kan het volgende gebeuren. Bekijk de grafiek!
  2. SJURVM 12 mei 2017 18:58
    Novacyt reports storming sales start to 2017
    Group sales increased 25 per cent on a reported basis and 38 per cent at constant exchange rates driven by NOVAprep® growth and the acquisition of Primerdesign.

    The gross margin continued to improve and was up seven percentage points to 55 per cent. On a pro forma basis, the group achieved a further improvement in gross margin to 59 per cent.

    Losses at the EBITDA level were reduced to €2.3 million (a loss of €1.7m on a pro forma basis) compared with a €2.9m loss for 2015. Momentum towards near-term EBITDA profitability was demonstrated by an EBITDA loss of €0.7m in H2 compared with €1.6m in H1.

    Group CEO Graham Mullis (pictured) said: “I am delighted to report continued strong double-digit sales growth across the group in 2016. Our increased sales momentum reflects the acquisition of Primerdesign, a profitable high-growth molecular diagnostic business and successful investment in NOVAprep® commercial infrastructure.

    “We have delivered the fourth consecutive period of high double-digit NOVAprep® sales growth. Consequently, our gross margin has continued to improve and I expect the trajectory to profitability to continue to accelerate, as demonstrated by the run-rate EBITDA loss significantly reduced during the second half of 2016.

    “Furthermore, 2017 has started very strongly, with sales up over 70 per cent across the group and I look forward to updating our shareholders and the market of our continued progress during the year.”

    www.businessweekly.co.uk/news/biomedt...
  3. SJURVM 12 mei 2017 19:05
    www.businesswire.com/news/home/201702...

    The additional non-gynaecological approval in China for NOVAprep® brings the technology to multiple new cancer markets and reinforces our direct sales investment in China, which is already giving substantial growth of 100%+ in 2016 and is expected to deliver more in 2017. We reported strong 100%+ growth across the Asia Pacific region in 2016 and I look forward to updating our shareholders further with the progress we are making in the region during 2017
  4. SJURVM 21 juni 2017 13:14
    www.businesswire.com/news/home/201706...

    Graham Mullis, Group CEO of Novacyt, commented:

    “Momentum towards profitability has continued through H1 2017 and with the increased sales demand across the business we are pleased with progress in the Company’s financial performance. I look forward to updating shareholders of this financial progress in July 2017.
  5. forum rang 4 Chasse_Patate 3 juli 2017 09:32
    quote:

    PonziNL schreef op 19 september 2016 08:41:


    Hou dit fonds in de gaten!


    Zeg dat wel.
    De beursdag voor jouw bericht was dit fonds gesloten op 1,40.
    Nu staat het op 0,84, een verlies van 40%.
    Absoluut een fonds om in de gaten te houden.
    Op 13 juli hun revenue rapportage.
    Ik ben benieuwd!

  6. forum rang 4 Chasse_Patate 12 juli 2017 10:18
    quote:

    SJURVM schreef op 21 juni 2017 13:14:


    www.businesswire.com/news/home/201706...

    Graham Mullis, Group CEO of Novacyt, commented:

    “Momentum towards profitability has continued through H1 2017 and with the increased sales demand across the business we are pleased with progress in the Company’s financial performance. I look forward to updating shareholders of this financial progress in July 2017.


    Graham Mullis looks forward to updating shareholders of this financial progress in July 2017.

    Morgen de update.
    Vandaag hopelijk de laatste kans om in te stappen op deze lage koers!

24.611 Posts
Pagina: 1 2 3 4 5 6 ... 1231 »» | Laatste |Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

Novacyt Meer »

Koers 3,600   Verschil +0,04 (+1,12%)
Laag 3,500   Volume 1.317.064
Hoog 3,680   Gem. Volume 2.202.043
7 aug 2020 17:36
label premium

KOPEN OF VERKOPEN?

Het laatste advies leest u als IEX Premium-lid

Ontdek Premium
 
Quotedata: Amsterdam realtime by Euronext, other realtime by Cboe Europe Ltd.   US stocks: by NYSE & Cboe BZX Exchange, 15min delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by VWD Group Crypto data by Crypto Compare